Showing results (131-140 of 252) with videos related to

Sort By:
Pageof 26
American Journal of Hematology|April 23, 2013
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromesAsmita Mishra, Maria Corrales-Yepez, Najla Al Ali, et al.
Haematologica|February 1, 2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemiaAkriti G Jain, Somedeb Ball, Luis Aguirre, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 5, 2019
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic SyndromesRami S Komrokji, Sheng Wei, Adam W Mailloux, et al.
Leukemia|May 5, 2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromesLuis E Aguirre, Najla Al Ali, David A Sallman, et al.
Blood Advances|February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromesAnthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Blood Neoplasia|June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasmZhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Oncotarget|June 8, 2017
Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cellsSonia C Dolfi, Daniel J Medina, Aparna Kareddula, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2023
Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and OutcomesSara M Tinsley-Vance, Najla Al Ali, Somedeb Ball, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Pageof 26